High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer.
adjuvant chemotherapy
cancer
colon
high risk
stage II
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
08
2021
accepted:
21
09
2021
entrez:
11
11
2021
pubmed:
12
11
2021
medline:
12
11
2021
Statut:
epublish
Résumé
High-risk features, such as T4 disease, bowel obstruction, poorly/undifferentiated histology, lymphovascular, perineural invasion, and <12 lymph nodes sampled, indicate poor prognosis and define high-risk stage II disease in proficient mismatch repair stage II colon cancer (CC). The prognostic role of high-risk features in dMMR/MSI-H stage II CC is unknown. Similarly, the role of adjuvant therapy in high-risk stage II CC with dMMR/MSI-H (≥1 high-risk feature) has not been studied in prospective trials. The aim of this analysis of the National Cancer Database is to evaluate the prognostic value of high-risk features in stage II dMMR/MSI-H CC. Univariate (UVA) and multivariate (MVA) Cox proportional hazards (Cox-PH) models were built to assess the association between clinical and demographic characteristics and overall survival. Kaplan-Meier survival curves were generated with log-rank tests to evaluate the association between adjuvant chemotherapy in high-risk and low-risk cohorts separately. A total of 2,293 stage II CC patients have dMMR/MSI-H; of those, 29.5% ( High-risk features are prognostic in the setting of dMMR/MSI-H stage II CC. Adjuvant chemotherapy may improve survival specifically in patients ≥65 years and with high-risk features.
Sections du résumé
BACKGROUND
BACKGROUND
High-risk features, such as T4 disease, bowel obstruction, poorly/undifferentiated histology, lymphovascular, perineural invasion, and <12 lymph nodes sampled, indicate poor prognosis and define high-risk stage II disease in proficient mismatch repair stage II colon cancer (CC). The prognostic role of high-risk features in dMMR/MSI-H stage II CC is unknown. Similarly, the role of adjuvant therapy in high-risk stage II CC with dMMR/MSI-H (≥1 high-risk feature) has not been studied in prospective trials. The aim of this analysis of the National Cancer Database is to evaluate the prognostic value of high-risk features in stage II dMMR/MSI-H CC.
METHODS
METHODS
Univariate (UVA) and multivariate (MVA) Cox proportional hazards (Cox-PH) models were built to assess the association between clinical and demographic characteristics and overall survival. Kaplan-Meier survival curves were generated with log-rank tests to evaluate the association between adjuvant chemotherapy in high-risk and low-risk cohorts separately.
RESULTS
RESULTS
A total of 2,293 stage II CC patients have dMMR/MSI-H; of those, 29.5% (
CONCLUSION
CONCLUSIONS
High-risk features are prognostic in the setting of dMMR/MSI-H stage II CC. Adjuvant chemotherapy may improve survival specifically in patients ≥65 years and with high-risk features.
Identifiants
pubmed: 34760701
doi: 10.3389/fonc.2021.755113
pmc: PMC8575657
doi:
Types de publication
Journal Article
Langues
eng
Pagination
755113Informations de copyright
Copyright © 2021 Mohamed, Jiang, Philip, Diab, Behera, Wu, Alese, Shaib, Gaines, Balch, El-Rayes and Akce.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ther Adv Med Oncol. 2010 Jul;2(4):261-72
pubmed: 21789139
Cancer. 2016 Nov 15;122(21):3277-3287
pubmed: 27417445
Ann Oncol. 2012 Oct;23(10):2479-2516
pubmed: 23012255
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
J Natl Cancer Inst. 2016 Feb 01;108(7):
pubmed: 26839356
J Clin Oncol. 2015 Dec 10;33(35):4176-87
pubmed: 26527776
Int J Environ Res Public Health. 2016 Sep 08;13(9):
pubmed: 27618077
Future Oncol. 2011 Mar;7(3):467-74
pubmed: 21417908
Eur J Cancer. 2017 Nov;86:266-274
pubmed: 29055842
Int J Colorectal Dis. 2007 May;22(5):467-73
pubmed: 16947042
J Clin Oncol. 2011 Sep 1;29(25):3381-8
pubmed: 21788561
J Natl Cancer Inst. 2011 Jun 8;103(11):863-75
pubmed: 21597022
Ann Surg. 2006 Feb;243(2):212-22
pubmed: 16432354
J Gastrointest Oncol. 2013 Dec;4(4):397-408
pubmed: 24294512
Int J Colorectal Dis. 1987 Nov;2(4):187-9
pubmed: 3694015
J Gastrointest Oncol. 2015 Dec;6(6):676-84
pubmed: 26697201
Cancer. 1992 Sep 15;70(6):1493-7
pubmed: 1516000
Int J Cancer. 2016 Jul 1;139(1):187-93
pubmed: 26914273
J Clin Oncol. 2005 Jan 20;23(3):609-18
pubmed: 15659508
J Clin Oncol. 1993 Oct;11(10):1879-87
pubmed: 8410113
J Clin Oncol. 2010 Jul 10;28(20):3219-26
pubmed: 20498393
Am J Surg. 1996 Sep;172(3):236-8
pubmed: 8862074
J Clin Oncol. 1999 Nov;17(11):3553-9
pubmed: 10550154
J Clin Oncol. 2004 Aug 15;22(16):3408-19
pubmed: 15199089
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Dis Colon Rectum. 2008 May;51(5):503-7
pubmed: 18322753
Nat Rev Clin Oncol. 2010 Mar;7(3):174-7
pubmed: 20190798